ICER Devalues People With Rheumatoid Arthritis

  • LinkedIn | by: Robert M. Goldberg |
  • 03/29/2017 12:00 AM
N/A by N/A is licensed under N/A N/A
ICER recently had a meeting to discuss its latest study: "Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value."  Don't bother reading it. It ends like every other ICER report: It concludes no medicine is cost effective and it uses methodology that no economist can replicate. ICER's 'studies' are the cold fusion experiments of health care economics. 

I have released a report discussing the impact of ICERs approach on patients. It concludes that applying ICER's cost-effectiveness standard to all biologics developed for RA since 2000 (none are cost-effective according to ICER) would have harmed a lot of people with RA.

Between 1999 and 2014 there would have been 46689 more deaths under an ICER regime. Additionally, research suggests that since 1999 the life expectancy of people with RA who used new medicines could expect to live 10 years longer than those not treated. Hence under an ICER regime people with RA would have 466894 fewer life years (46689 x 10). 

Going forward, ICER claims new RA drugs are not cost effective either. 

ICER estimates that only 97000 people year for five years (486000) with RA would get two new drugs it reviewed: baricitinib and sarilumab. Both medicines were tested in people with RA whose disease didn’t respond to any other treatments or couldn’t tolerate any other medicines. 

 
Article Photo Credit: N/A by N/A is licensed under N/A N/A
Sign Up for Our Email Newsletter

RECENT NEWS

Baby formula shortage: ‘There is light at the end of the tunnel,’ former FDA exec says

Baby formula shortage: ‘There is light at the end of the tunnel,’ former FDA exec says

Peter Pitts, president of the Center for Medicine in the Public Interest, joins Yahoo Finance Live to discuss the ongoing...  Read more

Former FDA official rips Biden over handling of baby formula shortage: 'Smoke and mirrors'

Former FDA official rips Biden over handling of baby formula shortage: 'Smoke and mirrors'

Peter Pitts, a former FDA associate commissioner, joined 'Fox & Friends First' to discuss the Biden administration's hand...  Read more

Peter Pitts speaks to CNN about baby formula shortage
  • CNN
  • 05/13/2022 12:00 AM

Peter Pitts speaks to CNN about baby formula shortage

Former FDA Associate Commissioner Peter Pitts speaks with CNN on the shortage of baby formula on May 13, 2022....  Read more

DRUGWONKS BLOG